Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOMIRA RESEARCH (BIOM) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (43)	1/29/2000 2:10:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 72

Merrill Lynch Bulletin Biomira Inc........1/25/00 Andre Uddin, Ph D., Senior Analyst - We are maintaining our intermediate-term Buy and long term Accumulate rating on Biomira. - Biomira announced the initiatin of a second Phase II trial for the treatment of lung cancer with its second-generation cancer vaccine BLP-25 and a liposomal IL-2 (an immune stimulant) -- this trail is expected to involve 14-20 patients. The purpose of this trial is to determine if liposomal IL-2 enhances the immune stimulating properties of the cancer vaccine BLP-25. - The first Phase II trial results involving BLP-25 (being tested on lung cancer patients) are expected by Q3 '00. - We also expect a licensing agreement to be forged for Biomira's lead cancer vaccine, THERATOPE, being developed for the treatment of breast cancer later this year. This licensing agreement may also involve Biomira's second-generation cancer vaccine BLP-25. - Our valuation is currently only based on THERATOPE being commercialized, given that the Phase II results for BLP-25 have not been released.